As a valued subscriber to the wealth of resources published by Relias Media, we are sending this reminder that your new issue is now available online. The articles in this issue are listed below:
A retrospective cohort study from a single California hospital found the administration of probiotics to patients receiving antibiotics did not reduce the incidence of healthcare facility-onset Clostridioides difficile infection.
Inappropriate antibiotic use for a child with a viral respiratory infection is not a “one and done” error. Children who receive antibiotics when diagnosed with a viral respiratory infection are more likely to seek care for viral infections subsequently and to receive inappropriate antibiotics again.
Forty-eight immunocompetent children with adenovirus-associated central nervous system disease were described. Thirty-eight percent of patients died or experienced permanent neurologic sequelae.
Staphylococcus aureus, including methicillin-resistant S. aureus, is a frequent surface environmental contaminant on both children’s playgrounds and in adult fitness centers.
Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.
Financial Disclosure: Peer Reviewer Patrick Joseph, MD, is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Updates Author Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jonathan Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships to this field of study.
